A misinformation dispute in Japan over Arcturus Therapeutics' COVID-19 vaccine Kostaive (ARCT-154) saw an unprecedented twist in December, when local distributor Meiji Seika Pharma decided to pursue a lawsuit and internal investigation over an Amazon bestseller book.
Meiji Seika Pharma Files Japan Lawsuit Over Kostaive Misinformation
Mysterious Twist In Vaccine Saga
The Japanese pharma firm has sued a politician claiming defamatory actions on social media around its novel COVID-19 vaccine.

More from Japan
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.
With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.
Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.
More from Therapy Areas
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.